Erbitux filed for lung cancer in US
This article was originally published in Scrip
Executive Summary
ImClone Systems (Lilly) and Bristol-Myers Squibbhave filed for use of Erbitux (cetuximab) in the US as a first-line treatment in advanced non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy (cisplatin/vinorelbine).